These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 11053416)

  • 41. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Binding kinetics of antiricin single domain antibodies and improved detection using a B chain specific binder.
    Anderson GP; Bernstein RD; Swain MD; Zabetakis D; Goldman ER
    Anal Chem; 2010 Sep; 82(17):7202-7. PubMed ID: 20687583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cloning, expression, purification and characterization of a bispecific single-chain diabody against fluoroquinolones and sulfonamides in Escherichia coli.
    Chen M; Wen K; Tao X; Xie J; Wang L; Li Y; Ding S; Jiang H
    Protein Expr Purif; 2014 Aug; 100():19-25. PubMed ID: 24816423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High level prokaryotic expression of anti-Müllerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging.
    Ortega C; Herbet A; Richard S; Kersual N; Costa N; Pèlegrin A; Ducancel F; Couraud JY; Navarro-Teulon I; Boquet D
    J Immunol Methods; 2013 Jan; 387(1-2):11-20. PubMed ID: 22910001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromatographic and adsorptive behavior of a bivalent bispecific antibody and associated fragments.
    Kimerer LK; Niu B; Pabst TM; Zhai W; Hunter AK; Carta G
    J Chromatogr A; 2021 Jul; 1648():462181. PubMed ID: 33989897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
    Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
    MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemical synthesis of bispecific monoclonal antibodies: potential advantages in immunoassay systems.
    Cook AG; Wood PJ
    J Immunol Methods; 1994 May; 171(2):227-37. PubMed ID: 8195590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability.
    Martsev SP; Tsybovsky YI; Stremovskiy OA; Odintsov SG; Balandin TG; Arosio P; Kravchuk ZI; Deyev SM
    Protein Eng Des Sel; 2004 Jan; 17(1):85-93. PubMed ID: 14985541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains.
    Muyldermans S; Atarhouch T; Saldanha J; Barbosa JA; Hamers R
    Protein Eng; 1994 Sep; 7(9):1129-35. PubMed ID: 7831284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bivalent monoclonal IgY antibody formats by conversion of recombinant antibody fragments.
    Greunke K; Spillner E; Braren I; Seismann H; Kainz S; Hahn U; Grunwald T; Bredehorst R
    J Biotechnol; 2006 Jul; 124(2):446-56. PubMed ID: 16490273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generation of camelid VHH bispecific constructs via in-cell intein-mediated protein trans-splicing.
    Shibuya Y; Haga N; Asano R; Nakazawa H; Hattori T; Takeda D; Sugiyama A; Kurotani R; Kumagai I; Umetsu M; Makabe K
    Protein Eng Des Sel; 2017 Jan; 30(1):15-21. PubMed ID: 27881685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments.
    Gilliland LK; Norris NA; Marquardt H; Tsu TT; Hayden MS; Neubauer MG; Yelton DE; Mittler RS; Ledbetter JA
    Tissue Antigens; 1996 Jan; 47(1):1-20. PubMed ID: 8929708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies.
    Rouet R; Dudgeon K; Christie M; Langley D; Christ D
    J Biol Chem; 2015 May; 290(19):11905-17. PubMed ID: 25737448
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies.
    Muyldermans S; Lauwereys M
    J Mol Recognit; 1999; 12(2):131-40. PubMed ID: 10398404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells.
    Olafsen T; Rasmussen IB; Norderhaug L; Bruland OS; Sandlie I
    Immunotechnology; 1998 Oct; 4(2):141-53. PubMed ID: 9853955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli.
    Pack P; Plückthun A
    Biochemistry; 1992 Feb; 31(6):1579-84. PubMed ID: 1737014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.